Fig. 7: Increased C1QB⁺TREM2⁺APOE⁺ M2 macrophages in prostate ICC/IDC.

a Unsupervised graph-based clustering of all samples visualized by UMAP highlighted for myeloid clusters 4 and 18 delineated by benign-enriched and ICC/IDC-enriched prostate. The dotted area demarks a subcluster of cells increased in ICC/IDC-enriched regions compared to benign-enriched regions. b Violin plots of myeloid, monocyte, dendritic cell, and macrophage marker expression in clusters 4 and 18. c Feature plots of C1QB, TREM2, APOE, and M2 macrophage markers (CD163, MSR1, and MRC1) in clusters 4 and 18. d Violin plots of C1QB, TREM2, APOE, and M2 macrophage markers (CD163, MSR1, and MRC1) in clusters 4 and 18 separated by ICC/IDC-enriched and benign-enriched. e PssGSEA of hallmark pathways in ICC/IDC-enriched prostate compared to benign-enriched prostate cells in clusters 4 and 18. f Re-clustering of clusters 4 and 18 into six clusters (Mac0-Mac6) separated by ICC/IDC-enriched and benign-enriched prostate and demarked by the original clusters 4 and 18. g–i Violin plots of markers in Mac0-Mac6. j Kaplan–Meier and log-rank test of progression-free survival in the TCGA PanCancer Atlas Prostate Adenocarcinoma for C1QB, TREM2, APOE, CD163, MRC1, and MSR1 signature (C1QB⁺TREM2⁺APOE⁺ M2 Signature) by median expression (n = 492). Kaplan-Meier and long-rank test of disease-free survival (DFS) in the MSKCC Prostate Adenocarcinoma for C1QB, TREM2, APOE, CD163, MRC1, and MSR1 signature (C1QB⁺TREM2⁺APOE⁺ M2 Signature) by median expression (n = 131).